Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review

References

• Sturdee DW, Panay N. Recommendations for the management of postmenopausal vaginal atrophy. Climacteric 2010;13:509–22
   PubMed Web of Science ®Google Scholar
• Portman DJ, Gass ML. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the international society for the study of women’s sexual health and the North American menopause society. Climacteric 2014;17:557–63
   PubMed Web of Science ®Google Scholar
• Panay N. Genitourinary syndrome of the menopause – dawn of a new era? Climacteric 2015;18(Suppl 1):13–17
   PubMed Web of Science ®Google Scholar
• Muhleisen AL, Herbst-Kralovetz MM. Menopause and the vaginal microbiome. Maturitas 2016;91:42–50
   PubMed Web of Science ®Google Scholar
• Lamont R, Sobel J, Akins R, et al. The vaginal microbiome: new information about genital tract flora using molecular based techniques. Bjog 2011;118:533–49
   PubMed Web of Science ®Google Scholar
• Gajer P, Brotman RM, Bai G, et al. Temporal dynamics of the human vaginal microbiota. Sci Transl Med 2012;4:132ra52
   PubMed Web of Science ®Google Scholar
• Witkin SS, Linhares IM, Giraldo P, et al. An altered immunity hypothesis for the development of symptomatic bacterial vaginosis. Clin Infect Dis 2007;44:554–7
   PubMed Web of Science ®Google Scholar
• Wilson JD, Lee RA, Balen AH, et al. Bacterial vaginal flora in relation to changing oestrogen levels. Int J STD AIDS 2007;18:308–11
   PubMed Web of Science ®Google Scholar
• Wierman ME. Sex steroid effects at target tissues: mechanisms of action. Adv Physiol Educ 2007;31:26–33
   PubMed Web of Science ®Google Scholar
• MacBride MB, Rhodes DJ, Shuster LT. Vulvovaginal atrophy. Mayo Clin Proc 2010;85:87–94
   PubMed Web of Science ®Google Scholar
• McGroarty JA. Probiotic use of lactobacilli in the human female urogenital tract. FEMS Immunol Med Microbiol 1993;6:251–64
   PubMed Web of Science ®Google Scholar
• Redondo-Lopez V, Cook RL, Sobel JD. Emerging role of lactobacilli in the control and maintenance of the vaginal bacterial microflora. Rev Infect Dis 1990;12:856–72
   PubMedGoogle Scholar
• Archer DF. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010;17:194–203
   PubMed Web of Science ®Google Scholar
• Bachmann GA, Nevadunsky NS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician 2000;61:3090–6
   PubMed Web of Science ®Google Scholar
• Ruan X, Mueck AO. Impact of smoking on estrogenic efficacy. Climacteric 2015;18:38–46
   PubMed Web of Science ®Google Scholar
• Kanne B, Jenny J. [Local administration of low-dosed estriol and viable Lactobacillus acidophilus in the post-menopausal period]. Gynäkol Rundsch 1991;31:7–13 [German]
   PubMedGoogle Scholar
• Nappi RE, Palacios S. Impact of vulvovaginal atrophy on sexual health and quality of life at postmenopause. Climacteric 2014;17:3–9
   PubMed Web of Science ®Google Scholar
• Krychman M, Graham S, Bernick B, et al. The Women’s EMPOWER survey: women’s knowledge and awareness of treatment options for vulvar and vaginal atrophy remains inadequate. J Sex Med 2017;14:425–33
   PubMed Web of Science ®Google Scholar
• Weber MA, Limpens J, Roovers JP. Assessment of vaginal atrophy: a review. Int Urogynecol J 2015;26:15–28
   PubMed Web of Science ®Google Scholar
• Simon JA. Identifying and treating sexual dysfunction in postmenopausal women: the role of estrogen. J Womens Health (Larchmt) 2011;20:1453–65
   PubMed Web of Science ®Google Scholar
• Nappi RE, Kokot-Kierepa M. Women’s voices in the menopause: results from an international survey on vaginal atrophy. Maturitas 2010;67:233–8
   PubMed Web of Science ®Google Scholar
• Weber MA, Kleijn MH, Langendam M, et al. Local oestrogen for pelvic floor disorders: a systematic review. PLoS One 2015;10:e0136265
   PubMed Web of Science ®Google Scholar
• Baber RJ, Panay N, Fenton A, et al. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric 2016;19:109–50
   PubMed Web of Science ®Google Scholar
• de Villiers TJ, Gass ML, Haines CJ, et al. Global consensus statement on menopausal hormone therapy. Climacteric 2013;16:203–4
   PubMed Web of Science ®Google Scholar
• Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 2013;20:888–902
   PubMed Web of Science ®Google Scholar
• Lumsden MA, Davies M, Sarri G, et al. Diagnosis and management of menopause: the National Institute of Health and Care Excellence (NICE) guideline. JAMA Intern Med 2016;176:1205–6
   PubMed Web of Science ®Google Scholar
• Neves-e-Castro M, Birkhauser M, Samsioe G, et al. EMAS position statement: the ten point guide to the integral management of menopausal health. Maturitas 2015;81:88–92
   PubMed Web of Science ®Google Scholar
• Ortmann O, Lattrich C. The treatment of climacteric symptoms. Dtsch Arztebl Int 2012;109:316–23
   PubMed Web of Science ®Google Scholar
• Ortmann O, Doren M, Windler E, et al. Hormone therapy in perimenopause and postmenopause (HT). Interdisciplinary S3 guideline, association of the scientific medical societies in Germany AWMF 015/062-short version. Arch Gynecol Obstet 2011;284:343–55
   PubMed Web of Science ®Google Scholar
• Nikander E, Kilkkinen A, Metsa-Heikkila M, et al. A randomized placebo-controlled crossover trial with phytoestrogens in treatment of menopause in breast cancer patients. Obstet Gynecol 2003;101:1213–20
   PubMed Web of Science ®Google Scholar
• Bruyniks N, Biglia N, Palacios S, et al. Systematic indirect comparison of ospemifene versus local estrogens for vulvar and vaginal atrophy. Climacteric 2017;20:195–204
   PubMed Web of Science ®Google Scholar
• Iosif CS. Effects of protracted administration of estriol on the lower genito urinary tract in postmenopausal women. Arch Gynecol Obstet 1992;251:115–20
   PubMed Web of Science ®Google Scholar
• Palacios S. Advances in hormone replacement therapy: making the menopause manageable. BMC Womens Health 2008;8:22
   PubMedGoogle Scholar
• Suckling JA, Kennedy R, Lethaby A, et al. Local oestrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev 2006;4:1–103; Art. No.:CD001500
   Google Scholar
• Head KA. Estriol: safety and efficacy. Altern Med Rev 1998;3:101–13
   PubMedGoogle Scholar
• Englund DE, Elamsson KB, Johansson EDB. Bioavailability of oestriol. Acta Endocrinol 1982;99:136–40
   PubMedGoogle Scholar
• Keller PJ, Riedmann R, Fischer M. [Oestrone, oestradiol and oestriol content following intravaginal application of oestriol in the postmenopause]. Gynäkol Rundsch 1980;20:77–9 [German]
   PubMedGoogle Scholar
• Trinkaus M, Chin S, Wolfman W, et al. Should urogenital atrophy in breast cancer survivors be treated with topical estrogens? Oncologist 2008;13:222–31
   PubMed Web of Science ®Google Scholar
• Palacios S, Castelo-Branco C, Cancelo MJ, et al. Low-dose, vaginally administered estrogens may enhance local benefits of systemic therapy in the treatment of urogenital atrophy in postmenopausal women on hormone therapy. Maturitas 2005;50:98–104
   PubMed Web of Science ®Google Scholar
• Heimer GM, Englund DE. Plasma oestriol following vaginal administration: morning versus evening insertion and influence of food. Maturitas 1986;8:239–43
   PubMed Web of Science ®Google Scholar
• van der Vies J. The pharmacology of oestriol. Maturitas 1982;4:291–9
   PubMedGoogle Scholar
• Bergink EW. Oestriol receptor interactions: their biological importance and therapeutic implications. Acta Endocrinol 1980;(Suppl 233):9–16
   Google Scholar
• Lokuge S, Frey BN, Foster JA, et al. The rapid effects of estrogen: a mini-review. Behav Pharmacol 2010;21:465–72
   PubMed Web of Science ®Google Scholar
• Longcope C. Estriol production and metabolism in normal women. J Steroid Biochem 1984;20:959–62
   PubMedGoogle Scholar
• Fink RS, Collins WP, Papadaki L, et al. Vaginal oestriol: effective menopausal therapy not associated with endometrial hyperplasia. J Gynaecol Endocrinol 1985;I:1–11
   Google Scholar
• Genazzani AR, Inaudi P, la Rosa R, et al. Oestriol and the menopause: clinical and endocrinological results of vaginal administration. In: Fioretti P, Martini L, Melis GB, et al., editors. The menopause: clinical, endocrinological and pathophysiological aspects. Serono Symposium No. 39. London (New York): Academic Press; 1982:539–50
   Google Scholar
• Mattsson L-A, Cullberg G. Vaginal absorption of two estriol preparations: a comparative study in post-menopausal women. Acta Obstet Gynecol Scand 1983;62:393–6
   PubMed Web of Science ®Google Scholar
• Rauramo L, Punnonen R, Grönroos M. Serum oestrone, oestradiol and oestriol concentrations during oral oestradiol valerate and oestriol succinate therapy in ovariectomized women. Maturitas 1978;1:79–85
   PubMed Web of Science ®Google Scholar
• van Haaften M, Donker GH, Haspels AA, et al. Oestrogen concentrations in plasma, endometrium, myometrium and vagina of postmenopausal women, and effects of vaginal oestriol (E3) and oestradiol (E2) applications. J Steroid Biochem 1989;33:647–53
   PubMedGoogle Scholar
• Bundesgesundheitsamt (BGA), Kommission B4. [B. Processing Monograph Estriol]. Daz 1993;133:858 [German]
   Google Scholar
• Furuhjelm M, Karlgren E, Carlström K. Intravaginal administration of conjugated estrogens in premenopausal and postmenopausal women. Int J Gynaecol Obstet 1980;17:335–9
   PubMedGoogle Scholar
• Samsioe G. Urogenital aging–a hidden problem. Am J Obstet Gynecol 1998;178:S245–9
   PubMed Web of Science ®Google Scholar
• Donders G, Neven P, Moegele M, et al. Ultra-low-dose estriol and Lactobacillus acidophilus vaginal tablets (Gynoflor(®)) for vaginal atrophy in postmenopausal breast cancer patients on aromatase inhibitors: pharmacokinetic, safety, and efficacy phase I clinical study. Breast Cancer Res Treat 2014;145:371–9
   PubMed Web of Science ®Google Scholar
• Ponzone R, Biglia N, Jacomuzzi ME, et al. Vaginal oestrogen therapy after breast cancer: is it safe? Eur J Cancer 2005;41:2673–81
   PubMed Web of Science ®Google Scholar
• van Haaften M, Donker GH, Sie-Go DM, et al. Biochemical and histological effects of vaginal estriol and estradiol applications on the endometrium, myometrium and vagina of postmenopausal women. Gynecol Endocrinol 1997;11:175–85
   PubMed Web of Science ®Google Scholar
• Vooijs GP, Geurts TBP. Review of the endometrial safety during intravaginal treatment with estriol. Eur J Obstet Gynecol 1995;62:101–6
   PubMed Web of Science ®Google Scholar
• Buhling KJ, Eydeler U, Borregaard S, et al. Systemic bioavailability of estriol following single and repeated vaginal administration of 0.03 mg estriol containing pessaries. Arzneimittelforschung 2012;62:378–83
   PubMed Web of Science ®Google Scholar
• Cano A, Estevez J, Usandizaga R, et al. The therapeutic effect of a new ultra low concentration estriol gel formulation (0.005% estriol vaginal gel) on symptoms and signs of postmenopausal vaginal atrophy: results from a Pivotal Phase III Study. Menopause 2012;19:1130–9
   PubMed Web of Science ®Google Scholar
• Capobianco G, Wenger JM, Meloni GB, et al. Triple therapy with Lactobacilli acidophili, estriol plus pelvic floor rehabilitation for symptoms of urogenital aging in postmenopausal women. Arch Gynecol Obstet 2014;289:601–8
   PubMed Web of Science ®Google Scholar
• Griesser H, Skonietzki S, Fischer T, et al. Low dose estriol pessaries for the treatment of vaginal atrophy: a double-blind placebo-controlled trial investigating the efficacy of pessaries containing 0.2mg and 0.03mg estriol. Maturitas 2012;71:360–8
   PubMed Web of Science ®Google Scholar
• Jaisamrarn U, Triratanachat S, Chaikittisilpa S, et al. Ultra-low-dose estriol and lactobacilli in the local treatment of postmenopausal vaginal atrophy: a double-blind randomized trial followed by open-label maintenance therapy. Climacteric 2013;16:347–55
   PubMed Web of Science ®Google Scholar
• Caruso S, Cianci S, Amore FF, et al. Quality of life and sexual function of naturally postmenopausal women on an ultralow-concentration estriol vaginal gel. Menopause 2016;23:47–54
   PubMed Web of Science ®Google Scholar
• Barbes C, Boris S. Potential role of lactobacilli as prophylactic agents against genital pathogens. AIDS Patient Care STDS 1999;13:747–51
   PubMed Web of Science ®Google Scholar
• Schöni M, Graf F, Meier B. [Treatment of vaginal disorders with Döderlein bacteria]. Saz 1988;126:139–42 [German]
   Google Scholar
• Vaneechoutte M. The human vaginal microbial community. Res Microbiol 2017;168:811–25
   PubMed Web of Science ®Google Scholar
• Unlu C, Donders G. Use of lactobacilli and estriol combination in the treatment of disturbed vaginal ecosystem: a review. J Turk Ger Gynecol Assoc 2011;12:239–46
   PubMedGoogle Scholar
• Anahtar MN, Byrne EH, Doherty KE, et al. Cervicovaginal bacteria are a major modulator of host inflammatory responses in the female genital tract. Immunity 2015;42:965–76
   PubMed Web of Science ®Google Scholar
• Witkin SS, Linhares IM, Giraldo P. Bacterial flora of the female genital tract: function and immune regulation. Best Pract Res Clin Obstet Gynaecol 2007;21:347–54
   PubMed Web of Science ®Google Scholar
• Hummelen R, Macklaim JM, Bisanz JE, et al. Vaginal microbiome and epithelial gene array in post-menopausal women with moderate to severe dryness. PLoS One 2011;6:e26602
   PubMed Web of Science ®Google Scholar
• Shen J, Song N, Williams CJ, et al. Effects of low dose estrogen therapy on the vaginal microbiomes of women with atrophic vaginitis. Sci Rep 2016;6:24380
   PubMed Web of Science ®Google Scholar
• Borges S, Silva J, Teixeira P. The role of lactobacilli and probiotics in maintaining vaginal health. Arch Gynecol Obstet 2014;289:479–89
   PubMed Web of Science ®Google Scholar
• Kaiser RR, Michael-Hepp J, Weber W, et al. Absorption of estriol from vaginal tablets after single and repeated application in healthy, postmenopausal women. Therapiewoche 2000;3:2–8
   Google Scholar
• Feiks A, Grunberger W. [Treatment of atrophic vaginitis: does topical application allow a reduction in the oestrogen dose?]. Gynäkol Rundsch 1991;31(Suppl 2):268–71 [German]
   PubMedGoogle Scholar
• Sousa MS, Peate M, Jarvis S, et al. A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy. Ther Adv Med Oncol 2017;9:269–85
   PubMed Web of Science ®Google Scholar
• Buchholz S, Mogele M, Lintermans A, et al. Vaginal estriol-lactobacilli combination and quality of life in endocrine-treated breast cancer. Climacteric 2015;18:252–9
   PubMed Web of Science ®Google Scholar
• Donders G, Bellen G, Neven P, et al. Effect of ultra-low-dose estriol and lactobacilli vaginal tablets (Gynoflor(R)) on inflammatory and infectious markers of the vaginal ecosystem in postmenopausal women with breast cancer on aromatase inhibitors. Eur J Clin Microbiol Infect Dis 2015;34:2023–8
   PubMed Web of Science ®Google Scholar
• Kanne B, Patz B, Wackerle L. [Local treatment of vaginal infections with Doederlein bacteria and estriol in climacterium and senium.]. Frauenarzt 1986;3:35–40 [German]
   Google Scholar
• Barrons R, Tassone D. Use of Lactobacillus probiotics for bacterial genitourinary infections in women: a review. Clin Ther 2008;30:453–68
   PubMed Web of Science ®Google Scholar
• Panay N, Fenton A. Vulvovaginal atrophy–a tale of neglect. Climacteric 2014;17:1–2
   Web of Science ®Google Scholar